Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 660 clinical trials
Multi-CAR-T Cells Targeting B Cell Lymphomas

This study aims to evaluate safety and efficacy of a combination of 4th generation chimeric antigen receptor gene-modified T cells targeting B cell surface molecules including CD19 and alternative CARTs as booster and consolidation treatment for patients with highly resistant B cell lymphomas, including primary mediastinal B cell lymphoma (PMBCL) …

  • 0 views
  • 19 Feb, 2024
Tasquinimod for the Treatment of Relapsed or Refractory Myeloma

This study is the first study of tasquinimod, an inhibitor of S100A9, in patients with multiple myeloma.

multiple myeloma
measurable disease
  • 0 views
  • 19 Feb, 2024
Open Label Dose Escalation Study for the Safety and Efficacy of STP705 in Adult Patients With isSCC

This is an open label, dose escalation study to evaluate the safety and efficacy of intralesional injection of STP705 in adult patients with Cutaneous Squamous Cell Carcinoma in situ (isSCC, Bowen's disease). The purpose of this trial is to evaluate the safety, tolerability and efficacy of various doses of STP705 …

  • 0 views
  • 19 Feb, 2024
Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL

This study will evaluate the efficacy and safety of camrelizumab in combination with apatinib in in patients with relapsed or refractory diffuse large B cell lymphoma failed from second line chemotherapy.

high-grade lymphoma
pulmonary function test
creatinine clearance rate
blood transfusion
colony stimulating factor
  • 0 views
  • 19 Feb, 2024
Balloon Lithoplasty for Preparation of Severely Calcified Coronary Lesions

Severely calcified coronary stenoses are difficult to treat with percutaneous coronary intervention (PCI) using current techniques and there is little specific evidence on how to best treat these cases. It is hypothesized that balloon lithoplasty is superior to conventional balloons for lesion preparation of severely calcified coronary lesions before stent …

exercise stress test
coronary artery stenosis
coronary disease
exercise test
ischemia
  • 0 views
  • 19 Feb, 2024
Connexin Genotypes in Cystic Fibrosis

Background: There is wide variety in lung disease phenotype for the delta F508 (homozygous) genotype. A leukocyte driven inflammation is most important for the pathogenesis of pulmonary disease in CF. Blood cytokines correlate negatively with pulmonary function in delta F508 homozygous patients. Gap junction proteins might be of importance for …

fibrosis
pulmonary function test
cytokines
forced expiratory volume
diabetes
  • 0 views
  • 19 Feb, 2024
Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas

Subjects with Neurofibromatosis Type 2 (NF2) and progressive vestibular schwannoma (VS) will be treated with crizotinib administered orally. Crizotinib will be taken continuously until disease progression or unacceptable toxicity, in continuous treatment cycles of 28 days each, for a maximum of 12 cycles.

nf2 gene
crizotinib
schwartz
measurable disease
neutrophil count
  • 0 views
  • 19 Feb, 2024
A Study to Evaluate ICP-022 in Patients With R/R PCNSL and SCNSL

The phase II clinical study is to investigate the safety, tolerability, efficacy and pharmacokinetics of ICP-022.

b-cell lymphoma
diffuse large b-cell lymphoma
primary cns lymphoma
lymphoma
  • 0 views
  • 19 Feb, 2024
Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy in the Treatment of Osteosarcoma

This study is a open-lable, , single center, phase II clinical study. Target population is patients with locally resectable osteosarcoma. Study objective is to compare the efficacy and safety of camrelizumab in combination with adriamycin, cisplatin, ifosfamide and methotrexate in study population in China. Camrelizumab is a humanized anti-PD1 IgG4 …

methotrexate
resectable osteosarcoma
measurable disease
psychotropic
camrelizumab
  • 0 views
  • 19 Feb, 2024
CPI-613 in Combination With Bendamustine in Patients With Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma

The purpose of this study is to determine if it is possible to give CPI-613 with the drug Bendamustine for 2 days every 28 days without causing severe side effects. In addition, this study will also test the safety of CPI-613 when given in combination with Bendamustine.

cutaneous t-cell lymphoma
infertility
mycosis fungoides/sezary syndrome
hodgkin's disease
renal function test
  • 0 views
  • 19 Feb, 2024